Source: European Medicines Agency (EU) Revision Year: 2022 Publisher: UCB Pharma S.A., Allée de la Recherche 60, B-1070, Bruxelles, Belgium
Vimpat 50 mg film-coated tablets.
Vimpat 100 mg film-coated tablets.
Vimpat 150 mg film-coated tablets.
Vimpat 200 mg film-coated tablets.
| Pharmaceutical Form |
|---|
|
Film-coated tablet. Vimpat 50 mg film-coated tablets: Pinkish, oval film-coated tablets with approximate dimensions of 10.4 mm x 4.9 mm, and debossed with ‘SP’ on one side and ‘50’ on the other side. Vimpat 100 mg film-coated tablets: Dark yellow, oval film-coated tablets with approximate dimensions of 13.2 mm x 6.1 mm, and debossed with ‘SP’ on one side and ‘100’ on the other side. Vimpat 150 mg film-coated tablets: Salmon, oval film-coated tablets with approximate dimensions of 15.1 mm x 7.0 mm, and debossed with ‘SP’ on one side and ‘150’ on the other side. Vimpat 200 mg film-coated tablets: Blue, oval film-coated tablets with approximate dimensions of 16.6 mm x 7.8 mm, and debossed with ‘SP’ on one side and ‘200’ on the other side. |
Vimpat 50 mg film-coated tablets: Each film-coated tablet contains 50 mg lacosamide.
Vimpat 100 mg film-coated tablets: Each film-coated tablet contains 100 mg lacosamide.
Vimpat 150 mg film-coated tablets: Each film-coated tablet contains 150 mg lacosamide.
Vimpat 200 mg film-coated tablets: Each film-coated tablet contains 200 mg lacosamide.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Lacosamide |
Lacosamide is a functionalised amino acid. The precise mechanism by which lacosamide exerts its antiepileptic effect in humans remains to be fully elucidated. |
| List of Excipients |
|---|
|
Tablet core: Microcrystalline cellulose Tablet coat: Vimpat 50 mg film-coated tablets: Polyvinyl alcohol Vimpat 100 mg film-coated tablets: Polyvinyl alcohol Vimpat 150 mg film-coated tablets: Polyvinyl alcohol Vimpat 200 mg film-coated tablets: Polyvinyl alcohol |
Vimpat 50 mg film-coated tablets:
Packs of 14, 28, 56 and 168 film-coated tablets in PVC/PVDC blister sealed with an aluminium foil.
Packs of 14 × 1 and 56 × 1 film-coated tablets in PVC/PVDC perforated unit dose blisters sealed with an aluminium foil.
Packs of 60 film-coated tablets in HDPE bottle with a child-resistant closure.
Vimpat 100 mg film-coated tablets:
Packs of 14, 28, 56 and 168 film-coated tablets in PVC/PVDC blister sealed with an aluminium foil.
Packs of 14 × 1 and 56 × 1 film-coated tablets in PVC/PVDC perforated unit dose blisters sealed with an aluminium foil.
Packs of 60 film-coated tablets in HDPE bottle with a child-resistant closure.
Vimpat 150 mg film-coated tablets:
Packs of 14, 28 and 56 film-coated tablets in PVC/PVDC blister sealed with an aluminium foil.
Multipacks containing 168 (3 packs of 56 tablets) film-coated tablets in PVC/PVDC blister sealed with an aluminium foil.
Packs of 14 × 1 and 56 × 1 film-coated tablets in PVC/PVDC perforated unit dose blisters sealed with an aluminium foil.
Packs of 60 film-coated tablets in HDPE bottle with a child-resistant closure.
Vimpat 200 mg film-coated tablets:
Packs of 14, 28 and 56 film-coated tablets in PVC/PVDC blister sealed with an aluminium foil.
Multipacks containing 168 (3 packs of 56 tablets) film-coated tablets in PVC/PVDC blister sealed with an aluminium foil.
Packs of 14 × 1 and 56 × 1 film-coated tablets in PVC/PVDC perforated unit dose blisters sealed with an aluminium foil.
Packs of 60 film-coated tablets in HDPE bottle with a child-resistant closure.
Not all pack sizes may be marketed.
UCB Pharma S.A., Allée de la Recherche 60, B-1070, Bruxelles, Belgium
EU/1/08/470/001
EU/1/08/470/002
EU/1/08/470/003
EU/1/08/470/004
EU/1/08/470/005
EU/1/08/470/006
EU/1/08/470/007
EU/1/08/470/008
EU/1/08/470/009
EU/1/08/470/010
EU/1/08/470/011
EU/1/08/470/012
EU/1/08/470/020
EU/1/08/470/021
EU/1/08/470/022
EU/1/08/470/023
EU/1/08/470/024
EU/1/08/470/025
EU/1/08/470/026
EU/1/08/470/027
EU/1/08/470/028
EU/1/08/470/029
EU/1/08/470/030
EU/1/08/470/031
EU/1/08/470/032
EU/1/08/470/033
EU/1/08/470/034
EU/1/08/470/035
Date of first authorisation: 29 August 2008
Date of latest renewal: 31 July 2013
| Drug | Countries | |
|---|---|---|
| VIMPAT | Austria, Australia, Brazil, Canada, Cyprus, Estonia, Spain, Finland, France, Hong Kong, Ireland, Israel, Japan, Lithuania, Mexico, Netherlands, New Zealand, Poland, United Kingdom, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
